PLRG1 Antibody

What is the optimal antibody dilution range for detecting PLRG1 in Western blot experiments?

The optimal dilution for PLRG1 antibodies in Western blot applications depends on the specific antibody formulation and source. Based on validated protocols:

For optimal results, researchers should perform antibody titration experiments with their specific cell or tissue lysates. The expected molecular weight of PLRG1 is approximately 57 kDa, but the observed molecular weight typically ranges between 55-60 kDa on SDS-PAGE gels .

Which applications are most commonly validated for PLRG1 antibodies?

PLRG1 antibodies have been extensively validated for multiple laboratory applications across different research contexts:

Most PLRG1 antibodies show reactivity with human, mouse, and rat samples, though species cross-reactivity should be verified for each specific antibody .

How should one design experiments to study PLRG1's role in spliceosome assembly using antibody-based approaches?

Investigating PLRG1's function in spliceosome assembly requires carefully designed experimental approaches:

• Co-immunoprecipitation studies:

  • Use PLRG1 antibodies (e.g., sc-376171 or ab86050) at 3-5 μg per mg of lysate to pull down native protein complexes

  • Analyze co-precipitated proteins by mass spectrometry or Western blot for spliceosome components (CDC5L, SNEV/Prp19)

  • Include RNase treatment controls to distinguish RNA-dependent vs. direct protein interactions

• Chromatin immunoprecipitation followed by sequencing (ChIP-seq):

  • Optimize crosslinking conditions (1% formaldehyde for 10 minutes is standard)

  • Use 2-5 μg of PLRG1 antibody per ChIP reaction

  • Include appropriate controls (IgG, input)

  • Analyze for enrichment at genes with active splicing

• Immunofluorescence co-localization:

  • Use PLRG1 antibodies at 1:100-1:500 dilution

  • Co-stain with other spliceosome markers (SC35, PRP19)

  • Analyze nuclear speckle morphology and co-localization

  • Consider FRAP (Fluorescence Recovery After Photobleaching) to study dynamics

Research has shown that PLRG1 forms a complex with Pso4/SNEV/Prp19 and CDC5L that is involved in both pre-mRNA splicing and DNA repair. When designing experiments, consider that PLRG1 deficiency causes enhanced p53 phosphorylation and stabilization with increased γ-H2AX immunoreactivity, indicating an activated DNA damage response .

How can PLRG1 antibodies be used to investigate its role in DNA damage response pathways?

PLRG1's involvement in DNA damage response can be investigated using the following approach:

• Damage induction and temporal analysis:

  • Induce DNA damage using agents like etoposide, UV, or ionizing radiation

  • Perform time-course experiments (0-24h)

  • Use PLRG1 antibodies (1:1000 for WB) to track:

    • Protein level changes

    • Post-translational modifications

    • Subcellular relocalization

• Co-immunoprecipitation after damage:

  • Use PLRG1 antibodies (3-5 μg/mg lysate) to identify damage-specific interaction partners

  • Compare untreated vs. damaged conditions

  • Focus on WRN protein interactions (implicated in Werner syndrome)

  • Analyze by mass spectrometry or targeted Western blotting

• Proximity ligation assay (PLA):

  • Utilize PLRG1 antibodies (1:100-1:200) in combination with antibodies against:

    • γ-H2AX (damage marker)

    • p53 and phospho-p53

    • CDC5L and other spliceosome components

  • Quantify interaction signals at damage sites

Research has demonstrated that PLRG1 deficiency causes enhanced p53 phosphorylation and stabilization with increased γ-H2AX immunoreactivity. p53 downregulation rescues lethality in both PLRG1-deficient MEFs and zebrafish in vivo, showing that apoptosis resulting from PLRG1 deficiency is p53 dependent .

What are the most common causes of non-specific binding when using PLRG1 antibodies, and how can they be mitigated?

Non-specific binding issues with PLRG1 antibodies can be addressed through systematic troubleshooting:

For Western blotting specifically, researchers report that PLRG1 antibodies work most effectively when:

• Using RIPA buffer with protease inhibitors for extraction

• Denaturing samples at 95°C for 5 minutes in standard Laemmli buffer

• Transferring proteins to PVDF rather than nitrocellulose membranes

• Using 5% BSA for blocking rather than milk-based blockers

What considerations should be made when selecting a PLRG1 antibody for cross-species studies?

When conducting cross-species research with PLRG1 antibodies, several factors require careful consideration:

• Sequence homology analysis:

  • Human PLRG1 shares approximately:

    • 98% sequence identity with mouse/rat PLRG1

    • 70% sequence identity with zebrafish PLRG1

    • ~50% with plant homologs

• Epitope-specific considerations:

  • Antibodies targeting the C-terminal region (aa 450-514) show better cross-reactivity between mammals

  • Antibodies against the central WD-repeat region (aa 100-300) may have more limited species cross-reactivity

  • The N-terminal region shows higher sequence divergence between species

• Validated cross-reactivity:

  Antibody Source/ID	Human	Mouse	Rat	Other Species	Recommended Application
  Santa Cruz (E-12)	✓	✓	✓	Not reported	WB, IP, IF, ELISA
  Abcam (ab86050)	✓	✓	Not reported	Not reported	IHC-P, IP, WB
  Thermo/Bethyl (A301-940A)	✓	✓	Predicted (100% seq. identity)	Bovine (predicted)	WB, IP, IHC
  Sigma (HPA035931)	✓	Not reported	Not reported	Not reported	WB, IF, IHC

• Validation recommendations:

  • Always perform preliminary validation in each species of interest

  • Include known positive control samples from each species

  • Consider epitope mapping if cross-reactivity issues arise

  • For evolutionary studies, consider generating custom antibodies against highly conserved regions

Studies using PLRG1 antibodies across species have revealed that the protein's functional importance in pre-mRNA splicing, cell cycle control, and apoptosis regulation is conserved across vertebrates .

How can PLRG1 antibodies be optimized for proximity-dependent labeling approaches to map dynamic interaction networks?

Proximity-dependent labeling techniques offer powerful insights into PLRG1's dynamic interactome within the spliceosome:

• BioID/TurboID approach:

  • Generate PLRG1-BioID/TurboID fusion constructs

  • Validate expression and localization using PLRG1 antibodies (IF: 1:200)

  • Induce biotinylation (2-24h for BioID, 10min-2h for TurboID)

  • Verify biotinylation pattern matches endogenous PLRG1 localization

  • Capture biotinylated proteins and analyze by mass spectrometry

  • Validate key interactions by co-IP with PLRG1 antibodies (3μg per reaction)

• APEX2-based proximity labeling:

  • Generate PLRG1-APEX2 fusion proteins

  • Validate correct localization compared to endogenous PLRG1 by IF

  • Perform rapid labeling (1min biotin-phenol + H₂O₂)

  • Compare labeled proteins under normal vs. stress conditions

  • Validate with conventional PLRG1 antibody-based co-IP

• Split-BioID or split-APEX approaches:

  • Design with PLRG1 fused to one half and candidate partners (CDC5L, PRP19) to other half

  • Signal generation only occurs when proteins interact

  • Validate using PLRG1 antibodies to confirm expression levels

  • Map condition-dependent interactions (±DNA damage, ±transcription inhibition)

These techniques provide temporal and spatial resolution of PLRG1 interactions that conventional immunoprecipitation approaches cannot achieve. Research has shown that PLRG1 functions within the context of the Cdc5L complex, which is vital for spliceosome assembly and pre-mRNA splicing processes, making it an excellent candidate for proximity labeling studies .

What strategies can be employed to investigate post-translational modifications of PLRG1 using available antibodies?

Investigating post-translational modifications (PTMs) of PLRG1 requires specialized approaches:

• Immunoprecipitation-based enrichment:

  • Use PLRG1 antibodies (3-5μg per mg lysate) to enrich the protein

  • Elute under mild conditions to preserve PTMs

  • Analyze by:

    • Phospho-specific Western blotting (phospho-serine/threonine/tyrosine antibodies)

    • PTM-specific stains (Pro-Q Diamond for phosphorylation)

    • Mass spectrometry with PTM-enrichment methods

• Two-dimensional gel electrophoresis:

  • Immunoprecipitate PLRG1 using available antibodies

  • Separate by isoelectric focusing followed by SDS-PAGE

  • Detect with PLRG1 antibody (1:1000)

  • Identify PTM-dependent charge/mass shifts

  • Excise spots for mass spectrometry analysis

• Phosphatase/deubiquitinase treatment controls:

  • Split immunoprecipitated PLRG1 into treated/untreated samples

  • Treat with lambda phosphatase, USP deubiquitinases, or SUMO proteases

  • Compare migration patterns by Western blot

  • Shifts indicate presence of specific modifications

• Stress/stimulus response studies:

  • Expose cells to DNA damage agents, cell cycle modulators, or splicing inhibitors

  • Immunoprecipitate PLRG1 at various timepoints

  • Analyze PTM changes in response to stimuli

  • Correlate with functional outcomes (localization, complex formation)

Research indicates that PLRG1 may undergo regulatory phosphorylation as part of cell cycle control mechanisms, and its interaction with the DNA damage response pathway suggests potential for damage-induced modifications that could be investigated using these approaches .

How can PLRG1 antibodies be utilized to investigate its role in cancer progression and DNA repair mechanisms?

PLRG1's involvement in cancer biology can be investigated through several antibody-based approaches:

• Cancer tissue microarray analysis:

  • Use PLRG1 antibodies for IHC staining (1:50-1:200 dilution)

  • Compare expression patterns across cancer types and stages

  • Correlate with patient outcome data

  • Analyze subcellular localization changes in tumors

• DNA damage response pathway investigation:

  • Induce DNA damage in cancer vs. normal cell lines

  • Track PLRG1 recruitment to damage sites using IF (1:100-1:250)

  • Co-stain with γ-H2AX, 53BP1, or RAD51

  • Assess temporal recruitment patterns and retention time

  • Compare repair efficiency in PLRG1-depleted vs. control cells

• p53-dependent apoptosis analysis:

  • Use PLRG1 antibodies to monitor protein levels in p53-wild-type vs. mutant cancer models

  • Perform co-IP studies to assess PLRG1-p53 interactions under genotoxic stress

  • Analyze downstream apoptotic markers correlation with PLRG1 expression

  • Implement rescue experiments with p53 inhibitors in PLRG1-depleted cells

Research has demonstrated that PLRG1 deficiency causes enhanced p53 phosphorylation and stabilization, indicating an activated DNA damage response. The finding that p53 downregulation rescues lethality in PLRG1-deficient models highlights a potentially important relationship in cancer contexts where p53 is frequently mutated .

What methodological approaches should be considered when using PLRG1 antibodies to study splicing dysregulation in neurodegenerative diseases?

Investigating PLRG1's role in neurodegenerative disease-associated splicing defects requires specialized methodological considerations:

• Brain tissue analysis protocols:

  • For fixed human/mouse brain tissues:

    • Optimize antigen retrieval (TE buffer pH 9.0 recommended)

    • Use PLRG1 antibodies at 1:50-1:200 dilution for IHC

    • Co-stain with neuronal/glial markers

    • Perform quantitative analysis across brain regions

  • For frozen sections:

    • Brief fixation (10min 4% PFA)

    • Permeabilize with 0.2% Triton X-100

    • Use PLRG1 antibodies at 1:100-1:500 for IF

    • Co-stain with splicing machinery markers (SC35, U1-70K)

• Neuronal culture applications:

  • Primary neuron cultures:

    • Fixation: 4% PFA, 10 minutes at room temperature

    • Permeabilization: 0.1% Triton X-100, 15 minutes

    • Blocking: 5% normal goat serum, 1 hour

    • PLRG1 antibody incubation: 1:200 overnight at 4°C

    • Visualize nuclear speckle patterns and dendritic localization

• Splicing analysis in disease models:

  • Immunoprecipitate PLRG1-associated RNAs (RIP)

  • Identify disease-relevant splicing targets

  • Compare PLRG1 interactions with splicing machinery components in normal vs. disease states

  • Validate with minigene splicing assays

Research using PLRG1 antibodies has shown its essential role in pre-mRNA splicing as a component of the spliceosome. Given that splicing dysregulation is increasingly implicated in neurodegenerative diseases, PLRG1's potential involvement makes it an important research target in this context .

How can PLRG1 antibodies be integrated into single-cell analysis workflows to study splicing dynamics in heterogeneous tissues?

Incorporating PLRG1 antibodies into single-cell analytical frameworks enables unprecedented insights into splicing regulation across diverse cell populations:

• Single-cell imaging mass cytometry (IMC):

  • Metal-conjugate PLRG1 antibodies (typically lanthanide metals)

  • Combine with cell type markers and splicing regulators

  • Image tissue sections at subcellular resolution

  • Analyze cell type-specific PLRG1 expression patterns

  • Quantify nuclear speckle organization across cell types

  • Implementation recommendations:

    • Use highly specific PLRG1 antibodies (Abcam ab86050, Bethyl A301-940A)

    • Validate metal-conjugated antibodies against unconjugated versions

    • Include positive control tissues (HEK293 cell pellets)

• Spatial transcriptomics with protein co-detection:

  • Perform RNA-seq with spatial resolution

  • Add PLRG1 antibody staining (1:100-1:200)

  • Correlate PLRG1 protein levels with splicing events

  • Map tissue microenvironments with distinct splicing signatures

  • Key considerations:

    • Compatible fixation methods (4% PFA recommended)

    • Fluorophore selection to avoid spectral overlap with RNA detection

    • Image analysis algorithms to correlate protein/RNA patterns

• CITE-seq adaptation for splicing regulators:

  • Develop oligonucleotide-conjugated PLRG1 antibodies

  • Combine with cell surface markers

  • Integrate with single-cell RNA-seq

  • Correlate PLRG1 protein levels with global splicing patterns

  • Technical considerations:

    • Cell permeabilization optimization for nuclear factor detection

    • Antibody concentration titration (start at 1:50-1:100)

    • Validation with conventional flow cytometry

These approaches allow researchers to explore how PLRG1's function in the PRP19-CDC5L spliceosome complex varies across cell types within complex tissues, potentially revealing cell type-specific splicing regulation mechanisms relevant to development, homeostasis, and disease .

What are the critical considerations when using PLRG1 antibodies in conjunction with CRISPR gene editing for functional genomics studies?

CRISPR-based functional genomics of PLRG1 requires careful antibody implementation strategies:

• Validation of CRISPR editing efficiency:

  • Western blotting with PLRG1 antibodies (1:1000 dilution)

  • Use antibodies targeting different epitopes to confirm complete protein loss

  • Quantify knockdown efficiency via densitometry

  • Consider using PLRG1 antibodies that recognize different domains for indel detection

• Domain-specific functional rescue experiments:

  • CRISPR knockout followed by complementation with:

    • Full-length PLRG1

    • WD-repeat domain mutants

    • Truncation variants

  • Validate expression using PLRG1 antibodies (WB: 1:1000, IF: 1:200)

  • Assess functional rescue through:

    • Splicing reporter assays

    • Cell proliferation/apoptosis measurements

    • p53 pathway activity

• Genome-wide splicing perturbation analysis:

  • Generate PLRG1 conditional knockout or degron-tagged cell lines

  • Validate protein depletion by immunoblotting (1:500-1:2000)

  • Perform RNA-seq before/after depletion

  • Identify globally affected splicing events

  • Validate specific targets by RT-PCR and immunoprecipitation

Research has demonstrated that complete knockout of PLRG1 results in embryonic lethality at 1.5 days postfertilization in mice, highlighting the need for conditional or partial depletion systems. Additionally, PLRG1 deficiency causes enhanced p53 phosphorylation and stabilization, suggesting that p53 status should be carefully monitored in CRISPR-edited cell lines to avoid confounding effects from p53-dependent apoptosis .

How can immunoprecipitation with PLRG1 antibodies be combined with RNA-seq to identify splicing targets in different physiological contexts?

Integrating PLRG1 immunoprecipitation with RNA analyses provides powerful insights into context-specific splicing regulation:

• RNA Immunoprecipitation followed by sequencing (RIP-seq):

  • Protocol optimization:

    • Crosslinking: 0.1-0.3% formaldehyde, 10 minutes at room temperature

    • Cell lysis: Non-denaturing conditions to preserve RNA-protein interactions

    • Immunoprecipitation: 5-10 μg PLRG1 antibody per 10⁷ cells

    • Controls: IgG IP, input RNA, validation of known targets

  • Data analysis considerations:

    • Enrichment calculation relative to input and IgG controls

    • Motif analysis of bound RNAs

    • Structured RNA elements identification

    • Integration with known spliceosome binding patterns

• iCLIP (individual-nucleotide resolution UV crosslinking and immunoprecipitation):

  • Specialized implementation for PLRG1:

    • UV crosslinking (254nm) to capture direct RNA interactions

    • Stringent wash conditions (high salt, detergents)

    • PLRG1 antibody selection: IP-validated antibodies (Abcam ab86050, Santa Cruz sc-376171)

    • RNase titration for optimal fragment size

  • Analysis focus:

    • Exact binding sites with nucleotide resolution

    • Correlation with exon inclusion/exclusion events

    • Developmental or tissue-specific binding patterns

• Parallel RNA-seq and splice junction analysis:

  • Experimental design:

    • PLRG1 knockdown/knockout with validation by Western blot (1:1000)

    • RNA extraction from control and PLRG1-depleted samples

    • Deep sequencing to capture low-abundance isoforms

    • RT-PCR validation of key splicing changes

  • Computational pipeline:

    • Differential splicing algorithms (rMATS, MAJIQ)

    • Exon usage quantification

    • Correlation with PLRG1 binding data

    • Pathway analysis of affected transcripts

Research has demonstrated that PLRG1 functions within the context of the Cdc5L complex, which is vital for spliceosome assembly and pre-mRNA splicing processes. These integrated approaches can reveal how PLRG1 contributes to specific splicing decisions in different cell types or under varying conditions .

What controls and validations are essential when using PLRG1 antibodies for quantitative proteomics studies of spliceosome dynamics?

Rigorous controls are critical for accurate quantitative proteomic analysis of PLRG1 and spliceosome dynamics:

• Antibody specificity validation for immunoprecipitation:

  • Western blot confirmation of single band at expected molecular weight (57kDa)

  • Mass spectrometry verification of immunoprecipitated protein identity

  • Competition assays with immunizing peptide

  • Knockout/knockdown validation showing loss of signal

  • Critical controls:

    Control Type	Purpose	Implementation
    IgG control	Non-specific binding assessment	Same species/isotype as PLRG1 antibody
    Input	Protein abundance normalization	5-10% of starting material
    Knockout/knockdown	Specificity validation	siRNA or CRISPR targeting PLRG1
    Peptide competition	Epitope specificity	Pre-incubate antibody with excess immunizing peptide

• Quantitative proteomics workflow optimization:

  • Sample preparation considerations:

    • Mild lysis conditions to preserve complexes (50mM Tris, 150mM NaCl, 0.5% NP-40)

    • Nuclear extraction protocols for enrichment of nuclear splicing factors

    • On-bead digestion vs. elution strategies

  • Labeling approaches:

    • SILAC labeling for cell culture studies

    • TMT/iTRAQ for increased multiplexing

    • Label-free quantification with appropriate normalization

• Splicing state-specific analysis:

  • Experimental design strategies:

    • Synchronize cells to capture cell cycle-dependent changes

    • Transcription inhibition (α-amanitin, DRB) to capture assembled vs. free spliceosome

    • Compare pre/post splicing complexes using staged biochemical isolation

  • Validation approaches:

    • Orthogonal co-IP with other spliceosome components

    • Native gel analysis of complex integrity

    • Functional splicing assays correlating with proteomic findings

Research has established that PLRG1 forms a complex with Pso4/SNEV/Prp19 and CDC5L that is involved in both pre-mRNA splicing and DNA repair. Quantitative proteomics approaches can reveal how this complex composition and interactions change under different cellular conditions, providing insights into its dual functionality .

How can super-resolution microscopy be optimized using PLRG1 antibodies to visualize spliceosome assembly dynamics?

Super-resolution imaging of PLRG1 requires specialized protocols to visualize spliceosome dynamics:

• Sample preparation optimization for super-resolution:

  • Fixation considerations:

    • 4% PFA, 10 minutes at room temperature (standard)

    • 2% PFA + 0.2% glutaraldehyde (for STORM/PALM)

    • Methanol fixation (-20°C, 10 minutes) as alternative for epitope preservation

  • Immunolabeling optimization:

    • PLRG1 antibody dilution: 1:100-1:500

    • Secondary antibody selection: F(ab')2 fragments preferable

    • Buffer components: Glucose oxidase/catalase system for STORM

    • Mounting media: Specialized for specific super-resolution technique

• Technique-specific implementations:

  Technique	Resolution Limit	PLRG1 Antibody Considerations	Applications
  STED	~50-80nm	Directly labeled primary antibodies or bright secondary antibodies	Nuclear speckle organization
  STORM/PALM	~20-30nm	Photoswitchable fluorophore conjugation, high antibody specificity	Molecular-scale organization
  SIM	~100-120nm	Standard immunofluorescence protocols, bright fluorophores	Dynamic live-cell imaging
  Expansion Microscopy	~70nm	Standard immunolabeling before expansion	Preserved context visualization

• Multi-color imaging strategies:

  • PLRG1 co-visualization with:

    • Other spliceosome components (PRP19, CDC5L)

    • Splicing regulators

    • Newly synthesized RNA (EU incorporation)

    • Chromatin markers

  • Technical considerations:

    • Chromatic aberration correction

    • Sequential labeling for highly multiplexed imaging

    • Spectral unmixing for close emission spectra

Research has shown that PLRG1 is primarily localized to nuclear speckles and contains seven WD repeats that facilitate the formation of a tertiary propeller structure essential for its role in the multiprotein Cdc5L complex. Super-resolution microscopy can reveal how these structures are organized at the nanoscale level and how they change during splicing activation .

What considerations are important when developing PLRG1 antibody-based biosensors to monitor splicing activity in living cells?

Creating effective PLRG1-based biosensors for live-cell splicing dynamics requires careful design considerations:

• Antibody fragment engineering approaches:

  • scFv (single-chain variable fragment) derivation:

    • Clone variable regions from validated PLRG1 antibodies

    • Express as intrabodies with appropriate localization signals

    • Fuse to fluorescent proteins for visualization

    • Validate specificity in PLRG1 knockout cells

  • nanobody development:

    • Immunize camelids with purified human PLRG1

    • Select high-affinity binders by phage display

    • Characterize binding properties (KD < 100nM ideal)

    • Test for minimal interference with PLRG1 function

• FRET/BRET-based sensor designs:

  • Intramolecular sensors:

    • PLRG1 sandwiched between fluorescent proteins

    • Conformational changes alter FRET efficiency

    • Calibrate with known splicing modulators

  • Intermolecular sensors:

    • PLRG1 fused to donor fluorophore

    • Interaction partner (CDC5L/PRP19) fused to acceptor

    • Monitor complex assembly/disassembly in real-time

    • Correlation with splicing reporter output

• Splicing activity correlation approaches:

  • Functional validation requirements:

    • Splicing reporter systems (exon inclusion/exclusion)

    • Correlation of sensor signal with splicing outcomes

    • Perturbation experiments (splicing inhibitors)

    • Comparison with fixed-cell immunofluorescence patterns

• Advanced implementations:

  • CRISPR knock-in strategies:

    • Tag endogenous PLRG1 with split fluorescent proteins

    • Create conditional degron-tagged PLRG1 for acute depletion

    • Engineer analog-sensitive PLRG1 for chemical-genetic control

  • Optogenetic approaches:

    • Light-controlled PLRG1 recruitment to specific nuclear domains

    • Observation of subsequent spliceosome assembly

    • Correlation with splicing pattern changes